Challenges and Opportunities in the Oral Delivery of Recombinant Biologics - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Pharmaceutics Année : 2023

Challenges and Opportunities in the Oral Delivery of Recombinant Biologics

Résumé

Recombinant biological molecules are at the cutting-edge of biomedical research thanks to the significant progress made in biotechnology and a better understanding of subcellular processes implicated in several diseases. Given their ability to induce a potent response, these molecules are becoming the drugs of choice for multiple pathologies. However, unlike conventional drugs which are mostly ingested, the majority of biologics are currently administered parenterally. Therefore, to improve their limited bioavailability when delivered orally, the scientific community has devoted tremendous efforts to develop accurate cell-and tissue-based models that allow for the determination of their capacity to cross the intestinal mucosa. Furthermore, several promising approaches have been imagined to enhance the intestinal permeability and stability of recombinant biological molecules. This review summarizes the main physiological barriers to the oral delivery of biologics. Several preclinical in vitro and ex vivo models currently used to assess permeability are also presented. Finally, the multiple strategies explored to address the challenges of administering biotherapeutics orally are described.
Fichier principal
Vignette du fichier
Masloh et al., 2023.pdf (9.15 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04108844 , version 1 (28-05-2023)

Identifiants

Citer

Solene Masloh, Maxime Culot, Fabien Gosselet, Anne Chevrel, Leonardo Scapozza, et al.. Challenges and Opportunities in the Oral Delivery of Recombinant Biologics. Pharmaceutics, 2023, 15 (5), ⟨10.3390/pharmaceutics15051415⟩. ⟨hal-04108844⟩
18 Consultations
11 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More